Literature DB >> 12057842

Advanced glycation end products (AGE) and their receptor (RAGE) in the brain of patients with Creutzfeldt-Jakob disease with prion plaques.

Nobuyuki Sasaki1, Masayoshi Takeuchi, Hiroshi Chowei, Seiji Kikuchi, Yorihide Hayashi, Norihito Nakano, Hiroshi Ikeda, Sho-ichi Yamagishi, Tetsuyuki Kitamoto, Toshikazu Saito, Zenji Makita.   

Abstract

The objective of this study was to assess the pathological role of advanced glycation end products (AGE) and the receptor for AGE (RAGE) in Creutzfeldt-Jakob disease (CJD). We immunohistochemically investigated the occipital lobe of three patients with CJD containing with prion protein (PrP) plaques using anti-AGE and RAGE antibodies. Many PrP-positive plaques were observed in these patients, and the PrP-positive prion plaques also showed immunoreactivity for the anti-AGE antibody. Furthermore, many astrocytes contained-PrP positive granules, and the same astrocytes also contained many AGE- and RAGE-immunopositive granules. The staining pattern of these granules showed good concordance with that of PrP. These findings suggest that there may be a RAGE-mediated PrP degradation pathway in CJD as is the case for beta-amyloid protein in Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12057842     DOI: 10.1016/s0304-3940(02)00310-5

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  23 in total

Review 1.  Transmission of prions within the gut and towards the central nervous system.

Authors:  Gianfranco Natale; Michela Ferrucci; Gloria Lazzeri; Antonio Paparelli; Francesco Fornai
Journal:  Prion       Date:  2011-07-01       Impact factor: 3.931

Review 2.  Understanding RAGE, the receptor for advanced glycation end products.

Authors:  Angelika Bierhaus; Per M Humpert; Michael Morcos; Thoralf Wendt; Triantafyllos Chavakis; Bernd Arnold; David M Stern; Peter P Nawroth
Journal:  J Mol Med (Berl)       Date:  2005-08-24       Impact factor: 4.599

Review 3.  The receptor for advanced glycation endproducts is a mediator of toxicity by IAPP and other proteotoxic aggregates: Establishing and exploiting common ground for novel amyloidosis therapies.

Authors:  Andisheh Abedini; Julia Derk; Ann Marie Schmidt
Journal:  Protein Sci       Date:  2018-07       Impact factor: 6.725

4.  Advanced glycation end products enhance the proliferation and activation of hepatic stellate cells.

Authors:  Keiko Iwamoto; Keishi Kanno; Hideyuki Hyogo; Sho-Ichi Yamagishi; Masayoshi Takeuchi; Susumu Tazuma; Kazuaki Chayama
Journal:  J Gastroenterol       Date:  2008-05-06       Impact factor: 7.527

5.  Effect of natural flavonoids, stilbenes and caffeic acid oligomers on protein glycation.

Authors:  Kenroh Sasaki; Syuko Chiba; Fumihiko Yoshizaki
Journal:  Biomed Rep       Date:  2014-06-25

6.  RAGE gene polymorphisms in patients with multiple sclerosis.

Authors:  Zoltán Tiszlavicz; Zsofia Gyulai; Krisztina Bencsik; Zoltán Szolnoki; Agnes Katalin Kocsis; Ferenc Somogyvári; László Vécsei; Yvette Mándi
Journal:  J Mol Neurosci       Date:  2009-11       Impact factor: 3.444

7.  Uncoupling the roles of HLA-DRB1 and HLA-DRB5 genes in multiple sclerosis.

Authors:  Stacy J Caillier; Farren Briggs; Bruce A C Cree; Sergio E Baranzini; Marcelo Fernandez-Viña; Patricia P Ramsay; Omar Khan; Walter Royal; Stephen L Hauser; Lisa F Barcellos; Jorge R Oksenberg
Journal:  J Immunol       Date:  2008-10-15       Impact factor: 5.422

8.  RAGE binds preamyloid IAPP intermediates and mediates pancreatic β cell proteotoxicity.

Authors:  Andisheh Abedini; Ping Cao; Annette Plesner; Jinghua Zhang; Meilun He; Julia Derk; Sachi A Patil; Rosa Rosario; Jacqueline Lonier; Fei Song; Hyunwook Koh; Huilin Li; Daniel P Raleigh; Ann Marie Schmidt
Journal:  J Clin Invest       Date:  2018-01-16       Impact factor: 14.808

9.  Advanced glycation end products and receptor for advanced glycation end products in AA amyloidosis.

Authors:  Christoph Röcken; Rosemarie Kientsch-Engel; Sophie Mansfeld; Barbara Stix; Kay Stubenrauch; Bernd Weigle; Frank Bühling; Mona Schwan; Wolfgang Saeger
Journal:  Am J Pathol       Date:  2003-04       Impact factor: 4.307

10.  Clinical chorioamnionitis is characterized by changes in the expression of the alarmin HMGB1 and one of its receptors, sRAGE.

Authors:  Roberto Romero; Tinnakorn Chaiworapongsa; Zeynep Alpay Savasan; Youssef Hussein; Zhong Dong; Juan Pedro Kusanovic; Chong Jai Kim; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2012-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.